Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723457 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
A Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06723457 is a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 34 participants, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06723457, a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunotherapy that engages T-cells in the immune system to help redirect their killing effects against lymphoma cells. Lenalidomide can modulate the immune system to enhance killing effects of lymphoma by the immune system as well. Giving patients a combination of epcoritamab and lenalidomide may work better in treating refractory or relapsed immunodeficiency-related large B-cell lymphoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG Lenalidomide
- BIOLOGICAL Epcoritamab
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2029-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723457
The ClinicalTrials.gov registry entry for NCT06723457 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (26% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Refractory B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06723457 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06723457 about?
NCT06723457 is a clinical study titled "Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma". This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunothe...
What is the current status of trial NCT06723457?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2025-07-25. Estimated completion is 2029-02-18.
What conditions does trial NCT06723457 study?
This clinical trial studies the following conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT06723457?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Lenalidomide (DRUG), Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06723457?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723457 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 2
-
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
Recurrent B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.